GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
- Conditions
- VaricellaMeaslesMumpsRubella
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 398
- Registration Number
- NCT00406211
- Locations
- π©πͺ
GSK Investigational Site, Hamburg, Germany
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 365
- Registration Number
- NCT00405392
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT00404963
- Locations
- πΊπΈ
GSK Investigational Site, Evansville, Indiana, United States
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Drug: GW679769 (Casopitant) oral tablets
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00405080
- Locations
- πΊπΈ
GSK Investigational Site, Tacoma, Washington, United States
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00404586
- Locations
- π©πͺ
GSK Investigational Site, Hannover, Niedersachsen, Germany
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
- Conditions
- Gastroesophageal Reflux DiseaseReflux, Gastroesophageal
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 92
- Registration Number
- NCT00405119
- Locations
- π¦πΊ
GSK Investigational Site, Herston, Queensland, Australia
The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 93
- Registration Number
- NCT00404768
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00404378
- Locations
- πΊπΈ
GSK Investigational Site, Lenexa, Kansas, United States
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
- Conditions
- Asthma
- Interventions
- Drug: Fluticasone/Salmeterol HFA
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 132
- Registration Number
- NCT00404261
- Locations
- π¦πΊ
GSK Investigational Site, Perth, Western Australia, Australia
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT00404274
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States